Herpes Simplex, HIV Infections
Conditions
Keywords
Acyclovir, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Anus Diseases, Herpes Genitalis
Brief summary
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
Interventions
DRUGAcyclovir
Sponsors
Glaxo Wellcome
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have: * HIV infection with CD4 counts = or \> 100 cells/mm3. * Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years. * History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy. Concurrent Medication: Excluded: * Systemic antiherpes medication. * Interferon. Patients with the following prior conditions are excluded: History of hypersensitivity to acyclovir.
Countries
United States
Outcome results
None listed